Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
84%
Chemotherapy
54%
Non Small Cell Lung Cancer
42%
Venous Thromboembolism
36%
Death
32%
Adverse Event
30%
Neoplasm
29%
Clinical Trial
28%
Pharmacokinetics
27%
Epidermal Growth Factor Receptor
27%
Incidence
27%
Pharmacology
26%
Complication
24%
Toxicity
24%
Protein
23%
Solid Malignant Neoplasm
22%
Bevacizumab
22%
Anticarcinogen
22%
Drug
20%
Hypertension
19%
Thrombocytopenia
19%
Paclitaxel
18%
Lipid
18%
Nanoparticle
18%
Melphalan
18%
Amifostine
18%
Oprelvekin
18%
Canavanine
18%
Febrile Neutropenia
18%
Multiple Myeloma
18%
Tumor Vaccine
18%
Breast Cancer
18%
Lung Cancer
16%
Ciclonicate
15%
Disease
14%
Prostate Cancer
13%
Hematologic Malignancy
13%
Cytotoxicity
13%
Antiemetic Agent
13%
Bleeding
12%
Immunotherapy
12%
Zofran
12%
Immune Checkpoint Inhibitor
11%
Colorectal Carcinoma
11%
Capecitabine
11%
Gemcitabine
11%
Cohort Study
11%
Nausea and Vomiting
10%
Nivolumab
10%
Water
9%
Medicine and Dentistry
Patient
100%
Therapeutic Procedure
54%
Adverse Event
29%
Malignant Neoplasm
28%
Chemotherapy
23%
Development
23%
Neoplasm
21%
Drug Therapy
21%
Colorectal Carcinoma
19%
Anticarcinogen
18%
Oprelvekin
18%
Oncology
18%
Melphalan
18%
Amifostine
18%
Hematopoietic Cell
18%
Clinical Trial
17%
Age
16%
Non Small Cell Lung Cancer
14%
Death
13%
Diseases
13%
Immunotherapy
13%
Toxicity
12%
Pediatrics
12%
Immune Checkpoint Inhibitor
11%
Capecitabine
11%
Nivolumab
10%
Infusion
10%
Thrombocytopenia
10%
Venous Thromboembolism
10%
Comorbidity
10%
Radiation Therapy
9%
Solid Malignant Neoplasm
9%
Bisphosphonate
9%
Prostate Cancer
9%
Drug
9%
Venae cavae
9%
Programmed Cell Death
9%
Evolution
9%
Cancer Treatment
9%
Cancer Research
9%
Bleeding
9%
Osteonecrosis of the Jaw
9%
Antidiabetic Agent
9%
Metastatic Breast Cancer
9%
Neck
9%
Ventricular Fibrillation
9%
Kounis Syndrome
9%
Cytoprotection
9%
Cancer Cell
9%
Hodgkin's Lymphoma
9%
Nursing and Health Professions
Patient
51%
Chemotherapy
35%
Adult
22%
Thrombocytopenia
19%
Malignant Neoplasm
19%
Dose
18%
Oprelvekin
18%
Time
11%
Analysis
10%
Incidence
10%
Hematologic Malignancy
9%
Blood Clotting Factor 8
9%
Ciclonicate
9%
Metastasis
9%
Adverse Event
9%
Blood Clotting Factor 9
9%
Kidney Transplantation
9%
Death
9%
Solid Malignant Neoplasm
9%
Clinical Outcome
9%
Febrile Neutropenia
9%
Platelet Derived Growth Factor
9%
Metastatic Breast Cancer
9%
Delayed Graft Function
9%
Venous Thromboembolism
9%
Thrombosis
9%
Haemophilia A
9%
Complication
8%
Thrombocyte Transfusion
7%
Breast Cancer
7%
Procedures
7%
Colony Stimulating Factor
7%
Lung Cancer
6%
Toxicity
6%
Donor
6%
Graft Survival
5%
Neutropenia
5%